Weekly Digest – August 2025 Weekly Digest – August 2025 18 August 2025: Ifinatamab deruxtecan granted Breakthrough Therapy Designation by U.S. FDA for patients with pretreated extensive stage small cell lung cancer The U.S. FDA has granted Breakthrough Therapy Designation […]
Weekly Digest – August 2025 Weekly Digest – August 2025 18 August 2025: Izalontamab brengitecan (EGFRxHER3 ADC) granted Breakthrough Therapy Designation by U.S. FDA for patients with previously treated advanced EGFR-mutated non-small cell lung cancer The U.S. FDA granted Breakthrough […]
Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: Antengene’s ATG-022 (CLDN18.2 ADC) granted Breakthrough Therapy Designation for the treatment of gastric/gastroesophageal junction adenocarcinoma Antengene’s CLDN18.2-targeting ADC ATG-022 received Breakthrough Therapy Designation from China’s NMPA for […]
Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: LM-302 (CLDN18.2 ADC), a class 1 new drug, has again been granted Breakthrough Therapy designation, demonstrating global advancement in research and development Lixin Pharmaceuticals LM-302 (CLDN18.2 ADC), […]
Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: Mabwell’s CDH17-targeting ADC 7MW4911 receives IND clearance from FDA Mabwell’s CDH17-targeting ADC 7MW4911 received FDA IND clearance to begin Phase 1/2 trials in advanced colorectal cancer and […]
Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: Henlius licenses Phase 3 innovative HER2 ADC from GeneQuantum Henlius has licensed exclusive development and commercialization rights for GeneQuantum’s HER2-targeted ADC GQ1005 in China and selected overseas […]
